MAIA Biotechnology, Inc. Cash Flow Statement
MAIA|3 years of annual SEC 10-K data (FY2022-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$16M
FY2024
Free Cash Flow
N/A
FY2024
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2024
MAIA Biotechnology, Inc. used $16M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Net Income | -$23.3M | -$15.8M | -$12.6M |
| Operating Cash Flow | -$15.7M | -$12.1M | -$4.1M |